ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Melanoma ranks 17th among the most frequently diagnosed cancers, with an upward trend in incidence. Treatment of this cancer is based on surgical removal of the lesion, but when metastases or recurrence occur, immunotherapy or chemotherapy is used. Most of the drugs used are characterized by numerous side effects or drug resistance that appears after some time of use. Therefore, multi-drug therapy is more often considered. The aim of the study was to assess the nature of the pharmacodynamic interaction of five different cytostatics (in a fixed dose ratio of 1:1) using a mathematical-statistical method-isobolographic analysis. The experiments were conducted on four human malignant melanoma cell lines (A375, SK-MEL28, FM55M2, FM55P) and studied all possible (ten) pairs of combinations of five standard cancer chemotherapy drugs (based on the MTT test): cisplatin, mitoxantrone, docetaxel, vemurafenib, and selumetinib. Our experiments showed that the most advantageous combination was the combination of vemurafenib with docetaxel for human melanoma lines-statistically significant synergy interaction for three cell lines. Also noteworthy are the combinations: cisplatin with mitoxantrone, vemurafenib with selumetinib, and vemurafenib with mitoxantrone. From a therapeutic point of view, the worst combination is cisplatin with docetaxel and cisplatin with selumetinib (interaction with a tendency to antagonism for the two cell lines). Monotherapy for melanoma does not produce good results, so the best drug combinations are sought, which would improve long-term, durable patient response and overcome drug resistance. It would also be good if the combination used caused fewer side effects than monotherapy, and this could be achieved in the case of using synergistic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.